Latest Blogs, Articles, and More
The management of patients with hormone receptor (HR)-positive breast cancer continues to evolve, with phase 3 studies shedding light on the length of adjuvant anti-estrogen therapy, a novel treatment gaining approval, and new trials exploring combination strategies.
Metastatic breast cancer will strike 30% of all breast cancer survivors yet only 2% of funds go to research this deadly cancer.
Being offered the chance to be an inspiration isn't up to you. What you do with it afterwards, is.
Treatment with eribulin mesylate significantly extended overall survival (OS) compared with dacarbazine in patients with advanced soft tissue sarcoma, according to topline results from a phase 3 clinical trial.
The latest in cancer prevention, diagnosis & treatment.